Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
A Phase Ⅰ Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
연구 유형
연구 유형
등록 (예상)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Na An
- 전화번호: +86-010-63930582
- 이메일: anna@mail.ecspc.com
연구 장소
-
-
Beijing
-
Beijing, Beijing, 중국
- 모병
- Beijing Chaoyang Hospital, Capital Medical University
-
연락하다:
- Wenming Chen, Doctor
- 전화번호: 13910107759
- 이메일: 13910107759@163.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients fully understand and voluntarily participate in this study and sign informed consent;
- Aged 18-75 years, without gender limitation;
- Patients with relapsed or refractory multiple myeloma(confirmed by histologically or cytologically) who had received at least one prior line regular treatment;
- Patients have at least one of the following conditions:(1)Serum M protein≥10g/L;(2)Urine M protein≥200 mg/24h; (3)Serum free light chain(sFLC): κ/λ FLC ratio is abnormal and affected FLC ≥100mg /L
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;
Laboratory tests meet the following conditions:
- Absolute neutrophil count (ANC) ≥1.5x10^9/L (No G-CSF treatment within 1 week prior to the laboratory test);
- Platelet count ≥ 75x10^9/L (No platelet transfusion within 1 week prior to the laboratory test);
- Total bilirubin ≤1.5upper limit of normal (ULN);
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN;
- Creatinine clearance(Ccr) ≥30mL/min.
- Females of childbearing potential must have a negative serum beta human chorionic gonadotrophin (β-hCG) pregnancy test result prior to enrollment and must agree to use an effective contraception method for the duration of the study treatment and 7 months after the last dose of study therapy.
Males patients and their partners must agree to use an effective contraceptive method for the duration of the study treatment and 4 months after the last dose of study therapy.
-
Exclusion Criteria:
- Patients with amyloidosis or central nervous system invasion or on dialysis treatment.
- Life expectancy < 3 months.
- History of allergy to mitoxantrone hydrochloride or liposomes;or previous treatment with adriamycin or other anthracyclines, with the total cumulative dose (doxorubicin equivalent) ≥350 mg/m^2.
- History of allergy (except local injection reaction) or intolerance to bortezomib;or one of the following conditions occurred with prior bortezomib regimens: no treatment response (not reach MR),disease progression within 6 months after the end of last dose.
- History of contraindications or intolerance to dexamethasone.
- Any anti-myeloma drug treatment or radiotherapy within 4 weeks prior to the first dose; or enrolled in any other clinical trials of anti-myeloma drug within 3 months prior to the first dose.
- History of autologous hematopoietic stem cell transplantation within 6 months prior to screening.
- History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
- Adverse events from the previous treatment have not resolved to ≤ Grade 1 (except for alopecia, hyperpigmentation).
- Patients with persistent Grade≥2 peripheral neuropathy or Grade 1 peripheral neuropathy with pain.
- Patients with impaired cardiac function or significant cardiac disease.
- HBsAg/HBcAb positive with HBV-DNA titer higher than the lower limit of the test value of the research center, or HCV antibody positive with HCV-RNA titer higher than the lower limit of the test value of the research center,or human immunodeficiency virus (HIV) antibody positive.
- Patients with obvious digestive system dysfunction, which may affect intake, transport and absorption of the study drug.
- Active bacterial, fungal or viral infections that require systemic treatment within 1 week prior to the first dose
- Patients underwent major surgery within 6 weeks prior to the first dose, or had a surgical schedule during the study period;
- History of additional malignant tumor within 5 years, except for locally curable cancer that has been cured.
- Other medical conditions that, in the judgment of the investigator, may affect the patient's participation in this study.
- Pregnant or breastfeeding women;
Not suitable for this study as decided by the investigator due to other reasons.
-
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 12 mg/m ^ 2 dose group (ArmA)
Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle).
The dose of mitoxantrone hydrochloride liposome is 12 mg/m^2
|
Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
다른 이름들:
Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
다른 이름들:
Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
다른 이름들:
|
|
실험적: 16 mg/m ^ 2 dose group (ArmB)
Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle).
The dose of mitoxantrone hydrochloride liposome is 16 mg/m^2
|
Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
다른 이름들:
Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
다른 이름들:
Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
다른 이름들:
|
|
실험적: 20 mg/m ^ 2 dose group (ArmC)
Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle).
The dose of mitoxantrone hydrochloride liposome is 20 mg/m^2
|
Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
다른 이름들:
Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
다른 이름들:
Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment-emergent adverse events (TEAEs)
기간: From the initiation of the first dose to 28 days after the last dose
|
To indentify the incidence of TEAEs
|
From the initiation of the first dose to 28 days after the last dose
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective response rate (ORR)
기간: Throughout the study treatment(Up to 32 weeks)
|
ORR is defined as the proportion of patients who have a best overall response of partial response (PR),very good partial response(VGPR), complete response (CR) or stringent complete response (sCR) as per International Myeloma Working Group (IMWG)
|
Throughout the study treatment(Up to 32 weeks)
|
|
Clinical Benefit Rate(CBR)
기간: Throughout the study treatment(Up to 32 weeks)
|
CBR is defined as the proportion of patients who have a best overall response of minimal response(MR),PR,VGPR,CR or sCR as per IMWG
|
Throughout the study treatment(Up to 32 weeks)
|
|
Disease control rate(DCR)
기간: Throughout the study treatment(Up to 32 weeks)
|
DCR is defined as the proportion of patients who have a best overall response of stable disease (SD),MR,PR,VGPR,CR or sCR as per IMWG
|
Throughout the study treatment(Up to 32 weeks)
|
|
Duration of response (DoR)
기간: Throughout the study completion.(An average of 12 months)
|
DoR is defined as the time from the first assessment of PR,VGPR,CR orsCR until the date of first occurrence of progressive disease (PD) as per IMWG
|
Throughout the study completion.(An average of 12 months)
|
|
Progression-free survival (PFS)
기간: Throughout the study completion.(An average of 12 months)
|
PFS is defined as the time from the date of first dose until the date of first documented PD as per IMWG or death from any cause, whichever occurs first
|
Throughout the study completion.(An average of 12 months)
|
|
Overall survival (OS)
기간: Throughout the study completion.(An average of 36 months)
|
OS is defined as the time from the date of first dose until the date of death from any cause
|
Throughout the study completion.(An average of 36 months)
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Wenming Chen, Beijing Chaoyang Hospital Affiliated to Capital Medical University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (예상)
기본 완료
연구 완료 (예상)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 심혈관 질환
- 혈관 질환
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 신생물
- 림프 증식 장애
- 면역증식성 장애
- 혈액 질환
- 출혈성 장애
- 지혈 장애
- 파라단백혈증
- 혈액 단백질 장애
- 다발성 골수종
- 신생물, 형질세포
- 약물의 생리적 효과
- 약리작용의 분자기전
- 자율 작용제
- 말초 신경계 작용제
- 효소 억제제
- 진통제
- 감각 시스템 에이전트
- 항염증제
- 항종양제
- 항구토제
- 위장약
- 글루코 코르티코이드
- 호르몬
- 호르몬, 호르몬 대체물 및 호르몬 길항제
- 항종양제, 호르몬
- 프로테아제 억제제
- 토포이소머라제 II 억제제
- 토포이소머라제 억제제
- 덱사메타손
- 덱사메타손 아세테이트
- 비비 1101
- 보르테조밉
- 미톡산트론
기타 연구 ID 번호
기타 연구 ID 번호
- HE071-CSP-023
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .